Investigational drug · Phase 3
BGM0504
Not approved by FDA. In 5 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Type 2 Diabetes (T2DM), Overweight or Obese Participants Without Diabetes, Obesity.
Phase 3Last checked: Nov 19, 2026Latest source record: Oct 15, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
5
3 still active
All registered trials
17
Any phase or sponsor naming "BGM0504"
First trial start
2024
Oct 29, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "BGM0504", any sponsor or status.
Conditions studied
As listed on its trial records.
- Type 2 Diabetes (T2DM)
- Overweight or Obese Participants Without Diabetes
- Obesity
- Overweight or Obesity
Approved drugs for the same conditions: Type 2 diabetes · Obesity and weight management · Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "BGM0504" as an intervention, largest first.
- A Study of BGM0504 Injection in Participants With Obesity or OverweightPivotal-lookingCompleted
BrightGene New Bio-Medical Technology(Wuxi) Co.Ltd.Industry
NCT06704581 · 652 participants · Start Oct 29, 2024 · Primary completion Mar 17, 2026
Drug: 5 mg BGM0504 injection; 10 mg BGM0504 injection administered subcutaneously (SC) once a week and 2 more · For: Overweight or Obesity
Sites: Beijing, China
- A Study of BGM0504 in Participants With Type 2 DiabetesPivotal-lookingCompleted
BrightGene Bio-Medical Technology Co., Ltd.Industry
NCT06716216 · 553 participants · Start Jan 13, 2025 · Primary completion Aug 25, 2026
Drug: Drug: 5 mg BGM0504 Administered SC; Drug:10 mg BGM0504 Administered SC and 1 more · For: Type 2 Diabetes Mellitus (T2DM)
Sites: Beijing, China
- A Study of BGM0504 in Early T2DM With ObesityPivotal-lookingRecruiting
BrightGene Bio-Medical Technology Co., Ltd.Industry
NCT07743983 · 372 participants (planned) · Start Sep 17, 2026 · Primary completion Sep 30, 2028
Drug: BGM0504; semaglutide · For: Type 2 Diabetes (T2DM)
Sites: Nanjing, China
- A Study of BGM0504 in Poorly Controlled Type 2 Diabetes Patients Only Through Diet and ExercisePivotal-lookingCompleted
BrightGene Bio-Medical Technology Co., Ltd.Industry
NCT06716203 · 227 participants · Start Jan 3, 2025 · Primary completion Aug 13, 2026
Drug: Drug: 5 mg BGM0504 Administered SC; Drug: : 10 mg BGM0504 Administered SC and 1 more · For: Type 2 Diabetes Mellitus (T2DM)
Sites: Beijing, China
- A Study to Evaluate Efficacy and Safety of BGM0504 Tablets in Overweight or Obese Participants Without DiabetesPivotal-lookingRecruiting
BrightGene Bio-Medical Technology Co., Ltd.Industry
NCT07658560 · 200 participants (planned) · Start Jun 29, 2026 · Primary completion Feb 28, 2027
Drug: BGM0504 tablets; BGM0504 tablets and 3 more · For: Overweight or Obese Participants Without Diabetes
Sites: Beijing, China
- A Study of BGM0504 in Participants With Type 2 Diabetes in IndonesiaPivotal-lookingActive, not recruiting
BrightGene Bio-Medical Technology Co., Ltd.Industry
NCT07064486 · 152 participants · Start Jul 4, 2025 · Primary completion Apr 30, 2027
Drug: BGM0504; BGM0504 and 1 more · For: Type 2 Diabetes (T2DM)
Sites: Depok, Indonesia; Jakarta, Indonesia · 4 sites in all
BrightGene Bio-Medical Technology Co., Ltd.Industry
NCT07566572 · 144 participants · Start Mar 26, 2026 · Primary completion Aug 31, 2026
Drug: BGM0504 tablets · For: Chinese Healthy Volunteers
Sites: Hangzhou, China
- Bioequivalence Study of BGM0504 InjectionPivotal-lookingCompleted
BrightGene Bio-Medical Technology Co., Ltd.Industry
NCT07382908 · 144 participants · Start Dec 29, 2025 · Primary completion Apr 9, 2026
Drug: BGM0504 Injection multi-dose pen; BGM0504 Injection single-dose pen and 1 more · For: Overweight/Obesity
Sites: Hangzhou, China
- A Study of BGM0504 Evaluating Weight Loss in Overweight or Obese Chinese SubjectsPivotal-lookingCompleted
BrightGene Bio-Medical Technology Co., Ltd.Industry
NCT06973681 · 120 participants · Start Oct 13, 2023 · Primary completion Sep 13, 2024
Drug: BGM0504; BGM0504 and 2 more · For: Overweight or Obesity
Sites: Changsha, China
BrightGene Bio-Medical Technology Co., Ltd.Industry
NCT06911203 · 96 participants · Start Apr 9, 2025 · Primary completion Jan 14, 2026
Drug: BGM0504; Tirzepatide · For: Obesity
Sites: Beijing, China
Newest research
PubMed records naming it or its code names, newest first.
- Effectiveness, Safety and Pharmacokinetics of BGM0504, a Dual GLP-1/GIP Receptor Agonist, in Chinese Adults With Overweight or Obesity Without Diabetes: A Phase 2 Multicentre, Randomized, Double-Blind, Placebo-Controlled Trial.
Ji L, Yang G, Huang Y, et al. · Diabetes Obes Metab 2026
- Evaluation of the Safety, Efficacy and Pharmacokinetics of BGM0504 in Chinese Adults With Type 2 Diabetes: A Multicentre, Randomised, Controlled and Double-Blind Phase II Trial.
Jin P, Ji L, Huang Y, et al. · Diabetes Obes Metab 2026
- The safety, tolerability, pharmacokinetics and pharmacodynamics of an optimized dual GLP-1/GIP receptor agonist (BGM0504) in healthy volunteers: A dose-escalation Phase I study.
Fan Y, Yuan J, Dong L, et al. · Diabetes Obes Metab 2025
- Molecular dynamics-guided optimization of BGM0504 enhances dual-target agonism for combating diabetes and obesity.
Yuan J, Liu W, Jiang X, et al. · Sci Rep 2024
Also in development for Type 2 Diabetes (T2DM)
- ObicetrapibPhase 37 trials
NewAmsterdam Pharma · Lipidemia, Preclinical Alzheimer's Disease, Antioxidant Absorption
- ezetimibe FDCPhase 32 trials
NewAmsterdam Pharma · Lipidemia, Coronary Artery Disease, Plaque, Atherosclerotic
- F027Phase 31 trial
Shandong New Time Pharmaceutical Co., LTD · Type 2 Diabetes (T2DM)
- GZR101-80Phase 21 trial
Gan & Lee Pharmaceuticals. · Type 2 Diabetes (T2DM)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.